ID   UFO_HUMAN               Reviewed;         894 AA.
AC   P30530; Q8N5L2; Q9UD27;
DT   01-APR-1993, integrated into UniProtKB/Swiss-Prot.
DT   28-MAR-2018, sequence version 4.
DT   12-OCT-2022, entry version 225.
DE   RecName: Full=Tyrosine-protein kinase receptor UFO;
DE            EC=2.7.10.1 {ECO:0000269|PubMed:28076778};
DE   AltName: Full=AXL oncogene;
DE   Flags: Precursor;
GN   Name=AXL; Synonyms=UFO;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=2247464; DOI=10.1073/pnas.87.22.8913;
RA   Partanen J., Maekelae T.P., Alitalo R., Lehvaeslaiho H., Alitalo K.;
RT   "Putative tyrosine kinases expressed in K-562 human leukemia cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 87:8913-8917(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM SHORT), AND ROLE IN MYELOID LEUKEMIA.
RC   TISSUE=Fibroblast;
RX   PubMed=1656220; DOI=10.1128/mcb.11.10.5016-5031.1991;
RA   O'Bryan J.P., Frye R.A., Cogswell P.C., Neubauer A., Kitch B., Prokop C.,
RA   Espinosa R., le Beau M.M., Earp H., Liu E.T.;
RT   "AXL, a transforming gene isolated from primary human myeloid leukemia
RT   cells, encodes a novel receptor tyrosine kinase.";
RL   Mol. Cell. Biol. 11:5016-5031(1991).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM LONG).
RX   PubMed=1834974;
RA   Janssen J.W.G., Schulz A.S., Steenvoorden A.C.M., Schmidberger M.,
RA   Strehl S., Ambros P., Bartram C.R.;
RT   "A novel putative tyrosine kinase receptor with oncogenic potential.";
RL   Oncogene 6:2113-2120(1991).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057824; DOI=10.1038/nature02399;
RA   Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J., Lamerdin J.E.,
RA   Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M., Aerts A.,
RA   Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E., Caenepeel S.,
RA   Carrano A.V., Caoile C., Chan Y.M., Christensen M., Cleland C.A.,
RA   Copeland A., Dalin E., Dehal P., Denys M., Detter J.C., Escobar J.,
RA   Flowers D., Fotopulos D., Garcia C., Georgescu A.M., Glavina T., Gomez M.,
RA   Gonzales E., Groza M., Hammon N., Hawkins T., Haydu L., Ho I., Huang W.,
RA   Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., Larionov V.,
RA   Leem S.-H., Lopez F., Lou Y., Lowry S., Malfatti S., Martinez D.,
RA   McCready P.M., Medina C., Morgan J., Nelson K., Nolan M., Ovcharenko I.,
RA   Pitluck S., Pollard M., Popkie A.P., Predki P., Quan G., Ramirez L.,
RA   Rash S., Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A.,
RA   She X., Smith D., Slezak T., Solovyev V., Thayer N., Tice H., Tsai M.,
RA   Ustaszewska A., Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J.,
RA   Dubchak I., Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E.,
RA   Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M.,
RA   Rubin E.M., Lucas S.M.;
RT   "The DNA sequence and biology of human chromosome 19.";
RL   Nature 428:529-535(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM LONG).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 674-730.
RX   PubMed=8247543;
RA   Lee S.-T., Strunk K.M., Spritz R.A.;
RT   "A survey of protein tyrosine kinase mRNAs expressed in normal human
RT   melanocytes.";
RL   Oncogene 8:3403-3410(1993).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 677-730, SUBCELLULAR LOCATION, AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Colon tumor;
RX   PubMed=7896447; DOI=10.1002/ijc.2910600611;
RA   Craven R.J., Xu L.H., Weiner T.M., Fridell Y.-W., Dent G.A., Srivastava S.,
RA   Varnum B., Liu E.T., Cance W.G.;
RT   "Receptor tyrosine kinases expressed in metastatic colon cancer.";
RL   Int. J. Cancer 60:791-797(1995).
RN   [8]
RP   INTERACTION WITH LIGAND GAS6.
RX   PubMed=7854420; DOI=10.1038/373623a0;
RA   Varnum B.C., Young C., Elliott G., Garcia A., Bartley T.D., Fridell Y.W.,
RA   Hunt R.W., Trail G., Clogston C., Toso R.J., Yanagihara D., Bennett L.,
RA   Silber M., Merewether L.A., Tseng A., Escobar E., Liu E.T., Yamane H.K.;
RT   "Axl receptor tyrosine kinase stimulated by the vitamin K-dependent protein
RT   encoded by growth-arrest-specific gene 6.";
RL   Nature 373:623-626(1995).
RN   [9]
RP   INTERACTION WITH GAS6, AND ACTIVITY REGULATION.
RX   PubMed=8621659; DOI=10.1074/jbc.271.16.9785;
RA   Mark M.R., Chen J., Hammonds R.G., Sadick M., Godowski P.J.;
RT   "Characterization of Gas6, a member of the superfamily of G domain-
RT   containing proteins, as a ligand for Rse and Axl.";
RL   J. Biol. Chem. 271:9785-9789(1996).
RN   [10]
RP   PHOSPHORYLATION AT TYR-779; TYR-821 AND TYR-866, AND INTERACTION WITH GRB2;
RP   LCK; PIK3R1; PIK3R2 AND PLCG1.
RX   PubMed=9178760; DOI=10.1038/sj.onc.1201123;
RA   Braunger J., Schleithoff L., Schulz A.S., Kessler H., Lammers R.,
RA   Ullrich A., Bartram C.R., Janssen J.W.;
RT   "Intracellular signaling of the Ufo/Axl receptor tyrosine kinase is
RT   mediated mainly by a multi-substrate docking-site.";
RL   Oncogene 14:2619-2631(1997).
RN   [11]
RP   ROLE IN PROSTATIC CARCINOMA.
RX   PubMed=10403904; DOI=10.1046/j.1525-1500.1999.99034.x;
RA   Jacob A.N., Kalapurakal J., Davidson W.R., Kandpal G., Dunson N.,
RA   Prashar Y., Kandpal R.P.;
RT   "A receptor tyrosine kinase, UFO/Axl, and other genes isolated by a
RT   modified differential display PCR are overexpressed in metastatic prostatic
RT   carcinoma cell line DU145.";
RL   Cancer Detect. Prev. 23:325-332(1999).
RN   [12]
RP   ROLE IN BREAST CANCER.
RX   PubMed=11484958; DOI=10.1023/a:1011126330233;
RA   Berclaz G., Altermatt H.J., Rohrbach V., Kieffer I., Dreher E.,
RA   Andres A.C.;
RT   "Estrogen dependent expression of the receptor tyrosine kinase axl in
RT   normal and malignant human breast.";
RL   Ann. Oncol. 12:819-824(2001).
RN   [13]
RP   INTERACTION WITH NCK2; PIK3R3; SOCS1 AND TNS2.
RX   PubMed=12470648; DOI=10.1016/s0006-291x(02)02718-3;
RA   Hafizi S., Alindri F., Karlsson R., Dahlbaeck B.;
RT   "Interaction of Axl receptor tyrosine kinase with C1-TEN, a novel C1
RT   domain-containing protein with homology to tensin.";
RL   Biochem. Biophys. Res. Commun. 299:793-800(2002).
RN   [14]
RP   FUNCTION OF THE GAS6/AXL SIGNALING PATHWAY.
RX   PubMed=12364394; DOI=10.1161/01.res.0000036753.50601.e9;
RA   D'Arcangelo D., Gaetano C., Capogrossi M.C.;
RT   "Acidification prevents endothelial cell apoptosis by Axl activation.";
RL   Circ. Res. 91:E4-12(2002).
RN   [15]
RP   ROLE IN THYROID CARCINOMAS.
RX   PubMed=12490074; DOI=10.1089/105072502320908303;
RA   Ito M., Nakashima M., Nakayama T., Ohtsuru A., Nagayama Y., Takamura N.,
RA   Demedchik E.P., Sekine I., Yamashita S.;
RT   "Expression of receptor-type tyrosine kinase, Axl, and its ligand, Gas6, in
RT   pediatric thyroid carcinomas around Chernobyl.";
RL   Thyroid 12:971-975(2002).
RN   [16]
RP   INTERACTION WITH CBL AND GAS6, AND UBIQUITINATION.
RX   PubMed=15958209; DOI=10.1016/j.bbrc.2005.05.086;
RA   Valverde P.;
RT   "Effects of Gas6 and hydrogen peroxide in Axl ubiquitination and
RT   downregulation.";
RL   Biochem. Biophys. Res. Commun. 333:180-185(2005).
RN   [17]
RP   ACTIVITY REGULATION, AND FUNCTION.
RX   PubMed=15507525; DOI=10.1182/blood-2004-04-1469;
RA   Gallicchio M., Mitola S., Valdembri D., Fantozzi R., Varnum B.,
RA   Avanzi G.C., Bussolino F.;
RT   "Inhibition of vascular endothelial growth factor receptor 2-mediated
RT   endothelial cell activation by Axl tyrosine kinase receptor.";
RL   Blood 105:1970-1976(2005).
RN   [18]
RP   FUNCTION IN PLATELET ACTIVATION AND THROMBOTIC RESPONSE REGULATION.
RX   PubMed=15733062; DOI=10.1111/j.1538-7836.2005.01186.x;
RA   Gould W.R., Baxi S.M., Schroeder R., Peng Y.W., Leadley R.J.,
RA   Peterson J.T., Perrin L.A.;
RT   "Gas6 receptors Axl, Sky and Mer enhance platelet activation and regulate
RT   thrombotic responses.";
RL   J. Thromb. Haemost. 3:733-741(2005).
RN   [19]
RP   FUNCTION (MICROBIAL INFECTION).
RX   PubMed=17005688; DOI=10.1128/jvi.01157-06;
RA   Shimojima M., Takada A., Ebihara H., Neumann G., Fujioka K., Irimura T.,
RA   Jones S., Feldmann H., Kawaoka Y.;
RT   "Tyro3 family-mediated cell entry of Ebola and Marburg viruses.";
RL   J. Virol. 80:10109-10116(2006).
RN   [20]
RP   INTERACTION WITH GRB2; PIK3R1 AND PIK3R2, AND PHOSPHORYLATION AT TYR-779;
RP   TYR-821 AND TYR-866.
RX   PubMed=18346204; DOI=10.1111/j.1471-4159.2008.05343.x;
RA   Weinger J.G., Gohari P., Yan Y., Backer J.M., Varnum B., Shafit-Zagardo B.;
RT   "In brain, Axl recruits Grb2 and the p85 regulatory subunit of PI3 kinase;
RT   in vitro mutagenesis defines the requisite binding sites for downstream Akt
RT   activation.";
RL   J. Neurochem. 106:134-146(2008).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-884, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [22]
RP   FUNCTION OF THE GAS6/AXL SIGNALING PATHWAY.
RX   PubMed=18840707; DOI=10.1182/blood-2008-05-157073;
RA   Park I.K., Giovenzana C., Hughes T.L., Yu J., Trotta R., Caligiuri M.A.;
RT   "The Axl/Gas6 pathway is required for optimal cytokine signaling during
RT   human natural killer cell development.";
RL   Blood 113:2470-2477(2009).
RN   [23]
RP   INTERACTION WITH GRB2 AND TNK2.
RX   PubMed=19815557; DOI=10.1074/jbc.m109.072660;
RA   Pao-Chun L., Chan P.M., Chan W., Manser E.;
RT   "Cytoplasmic ACK1 interaction with multiple receptor tyrosine kinases is
RT   mediated by Grb2: an analysis of ACK1 effects on Axl signaling.";
RL   J. Biol. Chem. 284:34954-34963(2009).
RN   [24]
RP   FUNCTION (MICROBIAL INFECTION).
RX   PubMed=21501828; DOI=10.1016/j.chom.2011.03.012;
RA   Morizono K., Xie Y., Olafsen T., Lee B., Dasgupta A., Wu A.M., Chen I.S.;
RT   "The soluble serum protein Gas6 bridges virion envelope phosphatidylserine
RT   to the TAM receptor tyrosine kinase Axl to mediate viral entry.";
RL   Cell Host Microbe 9:286-298(2011).
RN   [25]
RP   FUNCTION (MICROBIAL INFECTION).
RX   PubMed=22156524; DOI=10.1128/jvi.06451-11;
RA   Shimojima M., Stroher U., Ebihara H., Feldmann H., Kawaoka Y.;
RT   "Identification of cell surface molecules involved in dystroglycan-
RT   independent Lassa virus cell entry.";
RL   J. Virol. 86:2067-2078(2012).
RN   [26]
RP   FUNCTION (MICROBIAL INFECTION).
RX   PubMed=22673088; DOI=10.1292/jvms.12-0176;
RA   Shimojima M., Kawaoka Y.;
RT   "Cell surface molecules involved in infection mediated by lymphocytic
RT   choriomeningitis virus glycoprotein.";
RL   J. Vet. Med. Sci. 74:1363-1366(2012).
RN   [27]
RP   FUNCTION (MICROBIAL INFECTION), AND REVIEW.
RX   PubMed=25277499; DOI=10.1016/j.virol.2014.09.009;
RA   Moller-Tank S., Maury W.;
RT   "Phosphatidylserine receptors: enhancers of enveloped virus entry and
RT   infection.";
RL   Virology 468:565-580(2014).
RN   [28]
RP   FUNCTION (MICROBIAL INFECTION), MUTAGENESIS OF LYS-567, CATALYTIC ACTIVITY,
RP   AND SUBCELLULAR LOCATION.
RX   PubMed=28076778; DOI=10.1016/j.celrep.2016.12.045;
RA   Meertens L., Labeau A., Dejarnac O., Cipriani S., Sinigaglia L.,
RA   Bonnet-Madin L., Le Charpentier T., Hafirassou M.L., Zamborlini A.,
RA   Cao-Lormeau V.M., Coulpier M., Misse D., Jouvenet N., Tabibiazar R.,
RA   Gressens P., Schwartz O., Amara A.;
RT   "Axl Mediates ZIKA Virus Entry in Human Glial Cells and Modulates Innate
RT   Immune Responses.";
RL   Cell Rep. 18:324-333(2017).
RN   [29]
RP   FUNCTION (MICROBIAL INFECTION), AND SUBCELLULAR LOCATION.
RX   PubMed=29379210; DOI=10.1038/s41564-017-0092-4;
RA   Chen J., Yang Y.F., Yang Y., Zou P., Chen J., He Y., Shui S.L., Cui Y.R.,
RA   Bai R., Liang Y.J., Hu Y., Jiang B., Lu L., Zhang X., Liu J., Xu J.;
RT   "AXL promotes Zika virus infection in astrocytes by antagonizing type I
RT   interferon signalling.";
RL   Nat. Microbiol. 3:302-309(2018).
RN   [30]
RP   FUNCTION (MICROBIAL INFECTION).
RX   PubMed=31311882; DOI=10.1128/mbio.01372-19;
RA   Strange D.P., Jiyarom B., Pourhabibi Zarandi N., Xie X., Baker C.,
RA   Sadri-Ardekani H., Shi P.Y., Verma S.;
RT   "Axl Promotes Zika Virus Entry and Modulates the Antiviral State of Human
RT   Sertoli Cells.";
RL   MBio 10:0-0(2019).
RN   [31]
RP   X-RAY CRYSTALLOGRAPHY (3.3 ANGSTROMS) OF 33-227 IN COMPLEX WITH GAS6,
RP   MUTAGENESIS OF GLU-63; GLU-66 AND THR-84, AND SUBUNIT.
RX   PubMed=16362042; DOI=10.1038/sj.emboj.7600912;
RA   Sasaki T., Knyazev P.G., Clout N.J., Cheburkin Y., Goehring W., Ullrich A.,
RA   Timpl R., Hohenester E.;
RT   "Structural basis for Gas6-Axl signalling.";
RL   EMBO J. 25:80-87(2006).
RN   [32]
RP   VARIANTS [LARGE SCALE ANALYSIS] MET-112; TRP-295; CYS-499 AND GLY-515.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Receptor tyrosine kinase that transduces signals from the
CC       extracellular matrix into the cytoplasm by binding growth factor GAS6
CC       and which is thus regulating many physiological processes including
CC       cell survival, cell proliferation, migration and differentiation.
CC       Ligand binding at the cell surface induces dimerization and
CC       autophosphorylation of AXL. Following activation by ligand, AXL binds
CC       and induces tyrosine phosphorylation of PI3-kinase subunits PIK3R1,
CC       PIK3R2 and PIK3R3; but also GRB2, PLCG1, LCK and PTPN11. Other
CC       downstream substrate candidates for AXL are CBL, NCK2, SOCS1 and TNS2.
CC       Recruitment of GRB2 and phosphatidylinositol 3 kinase regulatory
CC       subunits by AXL leads to the downstream activation of the AKT kinase.
CC       GAS6/AXL signaling plays a role in various processes such as
CC       endothelial cell survival during acidification by preventing apoptosis,
CC       optimal cytokine signaling during human natural killer cell
CC       development, hepatic regeneration, gonadotropin-releasing hormone
CC       neuron survival and migration, platelet activation, or regulation of
CC       thrombotic responses. Also plays an important role in inhibition of
CC       Toll-like receptors (TLRs)-mediated innate immune response.
CC       {ECO:0000269|PubMed:10403904, ECO:0000269|PubMed:11484958,
CC       ECO:0000269|PubMed:12364394, ECO:0000269|PubMed:12490074,
CC       ECO:0000269|PubMed:15507525, ECO:0000269|PubMed:15733062,
CC       ECO:0000269|PubMed:1656220, ECO:0000269|PubMed:18840707}.
CC   -!- FUNCTION: (Microbial infection) Acts as a receptor for lassa virus and
CC       lymphocytic choriomeningitis virus, possibly through GAS6 binding to
CC       phosphatidyl-serine at the surface of virion envelope.
CC       {ECO:0000269|PubMed:17005688, ECO:0000269|PubMed:21501828,
CC       ECO:0000269|PubMed:22156524, ECO:0000269|PubMed:25277499}.
CC   -!- FUNCTION: (Microbial infection) Acts as a receptor for Ebolavirus,
CC       possibly through GAS6 binding to phosphatidyl-serine at the surface of
CC       virion envelope. {ECO:0000269|PubMed:22673088}.
CC   -!- FUNCTION: (Microbial infection) Promotes Zika virus entry in glial
CC       cells, Sertoli cells and astrocytes (PubMed:28076778, PubMed:29379210,
CC       PubMed:31311882). Additionally, Zika virus potentiates AXL kinase
CC       activity to antagonize type I interferon signaling and thereby promotes
CC       infection (PubMed:28076778). Interferon signaling inhibition occurs via
CC       an SOCS1-dependent mechanism (PubMed:29379210).
CC       {ECO:0000269|PubMed:28076778, ECO:0000269|PubMed:29379210,
CC       ECO:0000269|PubMed:31311882}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-tyrosyl-[protein] = ADP + H(+) + O-phospho-L-tyrosyl-
CC         [protein]; Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA-
CC         COMP:10137, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858,
CC         ChEBI:CHEBI:82620, ChEBI:CHEBI:456216; EC=2.7.10.1;
CC         Evidence={ECO:0000255|PROSITE-ProRule:PRU10028,
CC         ECO:0000269|PubMed:28076778};
CC   -!- ACTIVITY REGULATION: Activated by GAS6-binding and subsequent
CC       autophosphorylation. {ECO:0000269|PubMed:15507525,
CC       ECO:0000269|PubMed:8621659}.
CC   -!- SUBUNIT: Heterodimer and heterotetramer with ligand GAS6. Interacts
CC       with CBL, GRB2, LCK, NCK2, PIK3R1, PIK3R2, PIK3R3, PLCG1, SOCS1 and
CC       TNS2. Part of a complex including AXL, TNK2 and GRB2, in which GRB2
CC       promotes AXL recruitment by TNK2. {ECO:0000269|PubMed:12470648,
CC       ECO:0000269|PubMed:15958209, ECO:0000269|PubMed:16362042,
CC       ECO:0000269|PubMed:18346204, ECO:0000269|PubMed:19815557,
CC       ECO:0000269|PubMed:7854420, ECO:0000269|PubMed:8621659,
CC       ECO:0000269|PubMed:9178760}.
CC   -!- INTERACTION:
CC       P30530; P00533: EGFR; NbExp=4; IntAct=EBI-2850927, EBI-297353;
CC       P30530; P29317: EPHA2; NbExp=2; IntAct=EBI-2850927, EBI-702104;
CC       P30530; Q14393-1: GAS6; NbExp=8; IntAct=EBI-2850927, EBI-20753849;
CC       P30530; P62993: GRB2; NbExp=4; IntAct=EBI-2850927, EBI-401755;
CC       P30530; P08238: HSP90AB1; NbExp=3; IntAct=EBI-2850927, EBI-352572;
CC       P30530; P27986: PIK3R1; NbExp=3; IntAct=EBI-2850927, EBI-79464;
CC       P30530; P0DTC2: S; Xeno; NbExp=9; IntAct=EBI-2850927, EBI-25474821;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:28076778,
CC       ECO:0000269|PubMed:29379210, ECO:0000269|PubMed:7896447}; Single-pass
CC       type I membrane protein {ECO:0000269|PubMed:7896447}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=Long;
CC         IsoId=P30530-1; Sequence=Displayed;
CC       Name=Short;
CC         IsoId=P30530-2; Sequence=VSP_005017;
CC   -!- TISSUE SPECIFICITY: Highly expressed in metastatic colon tumors.
CC       Expressed in primary colon tumors. Weakly expressed in normal colon
CC       tissue. {ECO:0000269|PubMed:7896447}.
CC   -!- PTM: Monoubiquitinated upon GAS6-binding. A very small proportion of
CC       the receptor could be subjected to polyubiquitination in a very
CC       transient fashion. {ECO:0000269|PubMed:15958209}.
CC   -!- PTM: Phosphorylated at tyrosine residues by autocatalysis, which
CC       activates kinase activity. {ECO:0000269|PubMed:18346204,
CC       ECO:0000269|PubMed:9178760}.
CC   -!- DISEASE: Note=AXL and its ligand GAS6 are highly expressed in thyroid
CC       carcinoma tissues, and might thus be involved in thyroid tumorigenesis.
CC       Overexpression of AXL and its ligand was also detected in many other
CC       cancers such as myeloproliferative disorders, prostatic carcinoma
CC       cells, or breast cancer.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. AXL/UFO subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/AXLID733ch19q13.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M76125; AAA61243.1; -; mRNA.
DR   EMBL; S65125; AAB20305.1; -; mRNA.
DR   EMBL; X57019; CAA40338.1; -; mRNA.
DR   EMBL; AC011510; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC032229; AAH32229.1; -; mRNA.
DR   CCDS; CCDS12574.1; -. [P30530-2]
DR   CCDS; CCDS12575.1; -. [P30530-1]
DR   PIR; A41527; A41527.
DR   RefSeq; NP_001690.2; NM_001699.5. [P30530-2]
DR   RefSeq; NP_068713.2; NM_021913.4. [P30530-1]
DR   PDB; 2C5D; X-ray; 3.30 A; C/D=33-227.
DR   PDB; 4RA0; X-ray; 3.07 A; C/D=33-227.
DR   PDB; 5U6B; X-ray; 2.84 A; A/B/C/D=514-818.
DR   PDB; 5VXZ; X-ray; 2.30 A; C/D=34-135.
DR   PDBsum; 2C5D; -.
DR   PDBsum; 4RA0; -.
DR   PDBsum; 5U6B; -.
DR   PDBsum; 5VXZ; -.
DR   AlphaFoldDB; P30530; -.
DR   SMR; P30530; -.
DR   BioGRID; 107036; 202.
DR   CORUM; P30530; -.
DR   IntAct; P30530; 240.
DR   MINT; P30530; -.
DR   STRING; 9606.ENSP00000301178; -.
DR   BindingDB; P30530; -.
DR   ChEMBL; CHEMBL4895; -.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugBank; DB12141; Gilteritinib.
DR   DrugCentral; P30530; -.
DR   GuidetoPHARMACOLOGY; 1835; -.
DR   GlyConnect; 1983; 12 N-Linked glycans (4 sites).
DR   GlyGen; P30530; 7 sites, 9 N-linked glycans (3 sites).
DR   iPTMnet; P30530; -.
DR   PhosphoSitePlus; P30530; -.
DR   BioMuta; AXL; -.
DR   DMDM; 239938818; -.
DR   CPTAC; CPTAC-1766; -.
DR   CPTAC; CPTAC-2791; -.
DR   EPD; P30530; -.
DR   jPOST; P30530; -.
DR   MassIVE; P30530; -.
DR   MaxQB; P30530; -.
DR   PaxDb; P30530; -.
DR   PeptideAtlas; P30530; -.
DR   PRIDE; P30530; -.
DR   ProteomicsDB; 54712; -. [P30530-1]
DR   ProteomicsDB; 54713; -. [P30530-2]
DR   ABCD; P30530; 23 sequenced antibodies.
DR   Antibodypedia; 30709; 1283 antibodies from 42 providers.
DR   CPTC; P30530; 2 antibodies.
DR   DNASU; 558; -.
DR   Ensembl; ENST00000301178.9; ENSP00000301178.3; ENSG00000167601.12. [P30530-1]
DR   Ensembl; ENST00000359092.7; ENSP00000351995.2; ENSG00000167601.12. [P30530-2]
DR   GeneID; 558; -.
DR   KEGG; hsa:558; -.
DR   MANE-Select; ENST00000301178.9; ENSP00000301178.3; NM_021913.5; NP_068713.2.
DR   UCSC; uc010ehj.5; human. [P30530-1]
DR   CTD; 558; -.
DR   DisGeNET; 558; -.
DR   GeneCards; AXL; -.
DR   GeneReviews; AXL; -.
DR   HGNC; HGNC:905; AXL.
DR   HPA; ENSG00000167601; Low tissue specificity.
DR   MalaCards; AXL; -.
DR   MIM; 109135; gene.
DR   neXtProt; NX_P30530; -.
DR   OpenTargets; ENSG00000167601; -.
DR   PharmGKB; PA25197; -.
DR   VEuPathDB; HostDB:ENSG00000167601; -.
DR   eggNOG; ENOG502QQQ3; Eukaryota.
DR   GeneTree; ENSGT00940000160232; -.
DR   InParanoid; P30530; -.
DR   OMA; IIRCSVQ; -.
DR   OrthoDB; 263089at2759; -.
DR   PhylomeDB; P30530; -.
DR   TreeFam; TF317402; -.
DR   BRENDA; 2.7.10.1; 2681.
DR   PathwayCommons; P30530; -.
DR   Reactome; R-HSA-4420097; VEGFA-VEGFR2 Pathway.
DR   SignaLink; P30530; -.
DR   SIGNOR; P30530; -.
DR   BioGRID-ORCS; 558; 16 hits in 1111 CRISPR screens.
DR   ChiTaRS; AXL; human.
DR   EvolutionaryTrace; P30530; -.
DR   GeneWiki; AXL_receptor_tyrosine_kinase; -.
DR   GenomeRNAi; 558; -.
DR   Pharos; P30530; Tchem.
DR   PRO; PR:P30530; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   RNAct; P30530; protein.
DR   Bgee; ENSG00000167601; Expressed in synovial joint and 204 other tissues.
DR   ExpressionAtlas; P30530; baseline and differential.
DR   Genevisible; P30530; HS.
DR   GO; GO:0015629; C:actin cytoskeleton; IDA:HPA.
DR   GO; GO:0009986; C:cell surface; IDA:UniProtKB.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0005615; C:extracellular space; IDA:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; IBA:GO_Central.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0043235; C:receptor complex; IBA:GO_Central.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0032036; F:myosin heavy chain binding; IEA:Ensembl.
DR   GO; GO:0043548; F:phosphatidylinositol 3-kinase binding; IEA:Ensembl.
DR   GO; GO:0001786; F:phosphatidylserine binding; IDA:UniProtKB.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; EXP:Reactome.
DR   GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; IBA:GO_Central.
DR   GO; GO:0001618; F:virus receptor activity; IDA:FlyBase.
DR   GO; GO:0031100; P:animal organ regeneration; IEA:Ensembl.
DR   GO; GO:0001974; P:blood vessel remodeling; IEA:Ensembl.
DR   GO; GO:0048469; P:cell maturation; IEP:UniProtKB.
DR   GO; GO:0016477; P:cell migration; IBA:GO_Central.
DR   GO; GO:0031668; P:cellular response to extracellular stimulus; IEA:Ensembl.
DR   GO; GO:0070301; P:cellular response to hydrogen peroxide; IEA:Ensembl.
DR   GO; GO:0035457; P:cellular response to interferon-alpha; IDA:UniProtKB.
DR   GO; GO:0071222; P:cellular response to lipopolysaccharide; IDA:UniProtKB.
DR   GO; GO:0097028; P:dendritic cell differentiation; IEP:UniProtKB.
DR   GO; GO:0034101; P:erythrocyte homeostasis; IEA:Ensembl.
DR   GO; GO:0051649; P:establishment of localization in cell; IEA:Ensembl.
DR   GO; GO:0021885; P:forebrain cell migration; IEA:Ensembl.
DR   GO; GO:0006954; P:inflammatory response; IEA:Ensembl.
DR   GO; GO:0045087; P:innate immune response; IEA:UniProtKB-KW.
DR   GO; GO:0001779; P:natural killer cell differentiation; IBA:GO_Central.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IBA:GO_Central.
DR   GO; GO:2000669; P:negative regulation of dendritic cell apoptotic process; IDA:UniProtKB.
DR   GO; GO:0032689; P:negative regulation of interferon-gamma production; IDA:UniProtKB.
DR   GO; GO:0051250; P:negative regulation of lymphocyte activation; IEA:Ensembl.
DR   GO; GO:0010936; P:negative regulation of macrophage cytokine production; IEA:Ensembl.
DR   GO; GO:0043524; P:negative regulation of neuron apoptotic process; IEA:Ensembl.
DR   GO; GO:0032720; P:negative regulation of tumor necrosis factor production; IEA:Ensembl.
DR   GO; GO:0007399; P:nervous system development; IBA:GO_Central.
DR   GO; GO:0051402; P:neuron apoptotic process; IEA:Ensembl.
DR   GO; GO:0001764; P:neuron migration; IEA:Ensembl.
DR   GO; GO:0097350; P:neutrophil clearance; IEA:Ensembl.
DR   GO; GO:0042698; P:ovulation cycle; IEA:Ensembl.
DR   GO; GO:0006909; P:phagocytosis; IDA:UniProtKB.
DR   GO; GO:0030168; P:platelet activation; IBA:GO_Central.
DR   GO; GO:0001961; P:positive regulation of cytokine-mediated signaling pathway; IDA:UniProtKB.
DR   GO; GO:0033674; P:positive regulation of kinase activity; IBA:GO_Central.
DR   GO; GO:0032825; P:positive regulation of natural killer cell differentiation; IDA:UniProtKB.
DR   GO; GO:0048549; P:positive regulation of pinocytosis; IMP:CACAO.
DR   GO; GO:0051897; P:positive regulation of protein kinase B signaling; IBA:GO_Central.
DR   GO; GO:1903902; P:positive regulation of viral life cycle; IMP:FlyBase.
DR   GO; GO:0043491; P:protein kinase B signaling; IEA:Ensembl.
DR   GO; GO:0048678; P:response to axon injury; IEA:Ensembl.
DR   GO; GO:0032940; P:secretion by cell; IEA:Ensembl.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0007283; P:spermatogenesis; IEA:Ensembl.
DR   GO; GO:0034446; P:substrate adhesion-dependent cell spreading; IEA:Ensembl.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; IBA:GO_Central.
DR   GO; GO:0060068; P:vagina development; IEA:Ensembl.
DR   GO; GO:0048010; P:vascular endothelial growth factor receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0046718; P:viral entry into host cell; IMP:CACAO.
DR   CDD; cd00063; FN3; 2.
DR   Gene3D; 2.60.40.10; -; 4.
DR   InterPro; IPR003961; FN3_dom.
DR   InterPro; IPR036116; FN3_sf.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR036179; Ig-like_dom_sf.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR003599; Ig_sub.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   Pfam; PF00041; fn3; 2.
DR   Pfam; PF07714; PK_Tyr_Ser-Thr; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00060; FN3; 2.
DR   SMART; SM00409; IG; 2.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF48726; SSF48726; 2.
DR   SUPFAM; SSF49265; SSF49265; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50853; FN3; 2.
DR   PROSITE; PS50835; IG_LIKE; 2.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell membrane;
KW   Differentiation; Disulfide bond; Glycoprotein;
KW   Host cell receptor for virus entry; Host-virus interaction; Immunity;
KW   Immunoglobulin domain; Innate immunity; Kinase; Membrane;
KW   Nucleotide-binding; Oncogene; Phosphoprotein; Proto-oncogene; Receptor;
KW   Reference proteome; Repeat; Signal; Transferase; Transmembrane;
KW   Transmembrane helix; Tyrosine-protein kinase; Ubl conjugation.
FT   SIGNAL          1..25
FT                   /evidence="ECO:0000255"
FT   CHAIN           26..894
FT                   /note="Tyrosine-protein kinase receptor UFO"
FT                   /id="PRO_0000024481"
FT   TOPO_DOM        26..451
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        452..472
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        473..894
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          27..128
FT                   /note="Ig-like C2-type 1"
FT   DOMAIN          139..222
FT                   /note="Ig-like C2-type 2"
FT   DOMAIN          227..331
FT                   /note="Fibronectin type-III 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          336..428
FT                   /note="Fibronectin type-III 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          536..807
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          26..92
FT                   /note="Interaction with GAS6"
FT   REGION          823..853
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          866..894
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        672
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10028"
FT   BINDING         542..550
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         567
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         703
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         779
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:18346204,
FT                   ECO:0000269|PubMed:9178760"
FT   MOD_RES         821
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:18346204,
FT                   ECO:0000269|PubMed:9178760"
FT   MOD_RES         866
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:18346204,
FT                   ECO:0000269|PubMed:9178760"
FT   MOD_RES         884
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976"
FT   CARBOHYD        43
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        157
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        198
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        339
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        345
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        401
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        56..117
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114"
FT   DISULFID        160..205
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114"
FT   VAR_SEQ         429..437
FT                   /note="Missing (in isoform Short)"
FT                   /evidence="ECO:0000303|PubMed:1656220"
FT                   /id="VSP_005017"
FT   VARIANT         112
FT                   /note="T -> M (in dbSNP:rs35202236)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_045596"
FT   VARIANT         266
FT                   /note="D -> N (in dbSNP:rs7249222)"
FT                   /id="VAR_057990"
FT   VARIANT         295
FT                   /note="R -> W (in a lung neuroendocrine carcinoma sample;
FT                   somatic mutation; dbSNP:rs751738506)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_045597"
FT   VARIANT         499
FT                   /note="R -> C (in a gastric adenocarcinoma sample; somatic
FT                   mutation; dbSNP:rs747576071)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041877"
FT   VARIANT         515
FT                   /note="S -> G (in dbSNP:rs1240393707)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041878"
FT   MUTAGEN         63
FT                   /note="E->R: Slightly reduced affinity for GAS6."
FT                   /evidence="ECO:0000269|PubMed:16362042"
FT   MUTAGEN         66
FT                   /note="E->R: Reduced affinity for GAS6."
FT                   /evidence="ECO:0000269|PubMed:16362042"
FT   MUTAGEN         84
FT                   /note="T->R: Reduced affinity for GAS6."
FT                   /evidence="ECO:0000269|PubMed:16362042"
FT   MUTAGEN         567
FT                   /note="K->M: Catalytically inactive mutant."
FT                   /evidence="ECO:0000269|PubMed:28076778"
FT   CONFLICT        303
FT                   /note="T -> P (in Ref. 3; AAB20305/CAA40338)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        338
FT                   /note="E -> K (in Ref. 2; AAA61243)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        430
FT                   /note="Q -> E (in Ref. 3; AAB20305/CAA40338)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        639
FT                   /note="D -> G (in Ref. 3; AAB20305/CAA40338)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        696
FT                   /note="K -> I (in Ref. 7; no nucleotide entry)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        764
FT                   /note="Q -> R (in Ref. 5; AAH32229)"
FT                   /evidence="ECO:0000305"
FT   STRAND          37..39
FT                   /evidence="ECO:0007829|PDB:5VXZ"
FT   STRAND          44..46
FT                   /evidence="ECO:0007829|PDB:4RA0"
FT   STRAND          52..63
FT                   /evidence="ECO:0007829|PDB:5VXZ"
FT   STRAND          68..71
FT                   /evidence="ECO:0007829|PDB:5VXZ"
FT   STRAND          80..87
FT                   /evidence="ECO:0007829|PDB:5VXZ"
FT   STRAND          89..91
FT                   /evidence="ECO:0007829|PDB:5VXZ"
FT   STRAND          94..106
FT                   /evidence="ECO:0007829|PDB:5VXZ"
FT   HELIX           109..111
FT                   /evidence="ECO:0007829|PDB:5VXZ"
FT   STRAND          113..121
FT                   /evidence="ECO:0007829|PDB:5VXZ"
FT   STRAND          124..127
FT                   /evidence="ECO:0007829|PDB:5VXZ"
FT   STRAND          131..134
FT                   /evidence="ECO:0007829|PDB:5VXZ"
FT   STRAND          140..143
FT                   /evidence="ECO:0007829|PDB:4RA0"
FT   STRAND          148..150
FT                   /evidence="ECO:0007829|PDB:4RA0"
FT   STRAND          156..159
FT                   /evidence="ECO:0007829|PDB:4RA0"
FT   STRAND          161..163
FT                   /evidence="ECO:0007829|PDB:4RA0"
FT   STRAND          165..167
FT                   /evidence="ECO:0007829|PDB:4RA0"
FT   STRAND          170..175
FT                   /evidence="ECO:0007829|PDB:4RA0"
FT   STRAND          178..187
FT                   /evidence="ECO:0007829|PDB:4RA0"
FT   STRAND          190..194
FT                   /evidence="ECO:0007829|PDB:4RA0"
FT   STRAND          201..209
FT                   /evidence="ECO:0007829|PDB:4RA0"
FT   STRAND          212..215
FT                   /evidence="ECO:0007829|PDB:4RA0"
FT   STRAND          219..223
FT                   /evidence="ECO:0007829|PDB:4RA0"
FT   STRAND          515..517
FT                   /evidence="ECO:0007829|PDB:5U6B"
FT   HELIX           524..529
FT                   /evidence="ECO:0007829|PDB:5U6B"
FT   HELIX           533..535
FT                   /evidence="ECO:0007829|PDB:5U6B"
FT   STRAND          536..544
FT                   /evidence="ECO:0007829|PDB:5U6B"
FT   STRAND          546..556
FT                   /evidence="ECO:0007829|PDB:5U6B"
FT   STRAND          558..571
FT                   /evidence="ECO:0007829|PDB:5U6B"
FT   HELIX           576..590
FT                   /evidence="ECO:0007829|PDB:5U6B"
FT   STRAND          602..605
FT                   /evidence="ECO:0007829|PDB:5U6B"
FT   STRAND          616..621
FT                   /evidence="ECO:0007829|PDB:5U6B"
FT   HELIX           628..637
FT                   /evidence="ECO:0007829|PDB:5U6B"
FT   STRAND          638..640
FT                   /evidence="ECO:0007829|PDB:5U6B"
FT   HELIX           646..665
FT                   /evidence="ECO:0007829|PDB:5U6B"
FT   HELIX           675..677
FT                   /evidence="ECO:0007829|PDB:5U6B"
FT   STRAND          678..680
FT                   /evidence="ECO:0007829|PDB:5U6B"
FT   STRAND          686..688
FT                   /evidence="ECO:0007829|PDB:5U6B"
FT   STRAND          698..700
FT                   /evidence="ECO:0007829|PDB:5U6B"
FT   HELIX           713..715
FT                   /evidence="ECO:0007829|PDB:5U6B"
FT   HELIX           718..723
FT                   /evidence="ECO:0007829|PDB:5U6B"
FT   HELIX           728..743
FT                   /evidence="ECO:0007829|PDB:5U6B"
FT   HELIX           755..763
FT                   /evidence="ECO:0007829|PDB:5U6B"
FT   HELIX           776..785
FT                   /evidence="ECO:0007829|PDB:5U6B"
FT   HELIX           790..792
FT                   /evidence="ECO:0007829|PDB:5U6B"
FT   HELIX           796..809
FT                   /evidence="ECO:0007829|PDB:5U6B"
SQ   SEQUENCE   894 AA;  98337 MW;  262D3659218E3202 CRC64;
     MAWRCPRMGR VPLAWCLALC GWACMAPRGT QAEESPFVGN PGNITGARGL TGTLRCQLQV
     QGEPPEVHWL RDGQILELAD STQTQVPLGE DEQDDWIVVS QLRITSLQLS DTGQYQCLVF
     LGHQTFVSQP GYVGLEGLPY FLEEPEDRTV AANTPFNLSC QAQGPPEPVD LLWLQDAVPL
     ATAPGHGPQR SLHVPGLNKT SSFSCEAHNA KGVTTSRTAT ITVLPQQPRN LHLVSRQPTE
     LEVAWTPGLS GIYPLTHCTL QAVLSDDGMG IQAGEPDPPE EPLTSQASVP PHQLRLGSLH
     PHTPYHIRVA CTSSQGPSSW THWLPVETPE GVPLGPPENI SATRNGSQAF VHWQEPRAPL
     QGTLLGYRLA YQGQDTPEVL MDIGLRQEVT LELQGDGSVS NLTVCVAAYT AAGDGPWSLP
     VPLEAWRPGQ AQPVHQLVKE PSTPAFSWPW WYVLLGAVVA AACVLILALF LVHRRKKETR
     YGEVFEPTVE RGELVVRYRV RKSYSRRTTE ATLNSLGISE ELKEKLRDVM VDRHKVALGK
     TLGEGEFGAV MEGQLNQDDS ILKVAVKTMK IAICTRSELE DFLSEAVCMK EFDHPNVMRL
     IGVCFQGSER ESFPAPVVIL PFMKHGDLHS FLLYSRLGDQ PVYLPTQMLV KFMADIASGM
     EYLSTKRFIH RDLAARNCML NENMSVCVAD FGLSKKIYNG DYYRQGRIAK MPVKWIAIES
     LADRVYTSKS DVWSFGVTMW EIATRGQTPY PGVENSEIYD YLRQGNRLKQ PADCLDGLYA
     LMSRCWELNP QDRPSFTELR EDLENTLKAL PPAQEPDEIL YVNMDEGGGY PEPPGAAGGA
     DPPTQPDPKD SCSCLTAAEV HPAGRYVLCP STTPSPAQPA DRGSPAAPGQ EDGA
//
